Eyenovia (WKN: A2N6DV)
Seite 1 von 1 Neuester Beitrag: 13.12.22 14:35 | ||||
Eröffnet am: | 26.05.22 10:49 | von: Chalifmann3 | Anzahl Beiträge: | 23 |
Neuester Beitrag: | 13.12.22 14:35 | von: clint65 | Leser gesamt: | 5.750 |
Forum: | Hot-Stocks | Leser heute: | 2 | |
Bewertet mit: | ||||
Eyenovia, Inc. (EYEN)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
Quote Lookup
2.2000+0.0400 (+1.85%)
Good Luck!
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
OT: SPPI ist nicht pleite, Hamni bei 1,60 KE mitgezogen. Aber sie brauch Geld und die folgende Adcom kann zum gamechanger für das Unternehmen werden. Allerdings bin ich da auch eher vorsichtig; sie brauchen Geld und die MK ist relativ hoch.
uebrigens,ein echt klasse wert (kein biotech) finde ich noch diesen ipo-flopp aus 2014:
https://www.ariva.de/forum/gopro-ist-zukunft-534494
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
Gulf Keystone Petroleum Limited (GKP.L)
LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
Add to watchlist
Quote Lookup
228.00-8.00 (-3.39%)
Ocular Therapeutix, Inc. (OCUL)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Quote Lookup
5.92+0.51 (+9.43%)
https://www.ariva.de/forum/aeroclean-tech-wkn-a3c8hd-579622
https://www.ariva.de/forum/applied-dna-sciences-579780
IVERIC bio, Inc. (ISEE)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Quote Lookup
19.76+2.08 (+11.76%)
As of 10:40AM EDT. Market open.
Wir gewinnen nicht immer und ein bisschen Glück brauchen wir. Das wünsche ich dir! Ich hatte letztes Jahr sehr viel Glück und mir und meinen Eltern einige schöne Dinge gekauft! SPPI gerade einen Teil verkauft - risk reward stimmt dort nicht!
https://www.marketbeat.com/stocks/NASDAQ/EYEN/...campaign=SocialMedia
cytomX ist aehnlich gelagert wie sellas,aber mit deutlich groesserer üipeline und cashposi,koennte die biotechaktie der naechsten jahre werden,denn ich meine der einzige grund fuer den kursverfall ist,dass die noch nicht die richtige dosierung gefunden haben,das ist aber natuerlich kein problem und immer loesbar ,,,,..
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Quote Lookup
1.5500+0.3400 (+28.0992%)
https://www.conferencecalltranscripts.org/summary/?id=11561664
Werde heute verkaufen und wieder bei knapp über einem Dollar einsteigen in 2023 ... viel zu lange hier gewartet und mir einigen Gewinn entgehen lassen.